Hematologic recovery following autologous and allogeneic bone marrow transplantation.
Posttransplant hematologic recovery was compared between 9 autologous and 11 allogeneic marrow transplant patients who received similar marrow-lethal chemoradiotherapies before transplantation. Although the autotransplant patients were infused with much lower marrow doses compared with the allotransplant patients, they showed adequate hematologic recovery with acceptable risk. Regardless of marrow doses, delayed platelet recovery and failure of platelet recovery were observed in 7 patients. All of these patients experienced early transplantation-related complications before engraftment. Despite the limited number of patients, a number of myeloid progenitor cells (CFUC) infused correlated significantly with the period for recovery of polymorphonuclear cells in autologous marrow recipients while there was no significant correlation found between marrow dose and hematologic recovery in both groups of patients. Furthermore, autotransplant patients showed a characteristic recovery pattern of peripheral blood lymphocytes in an early posttransplant period, whic was not observed in allotransplant patients.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006410:Hematopoiesis; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000276:immunology / Q000628:therapy*; D007958:Leukocyte Count; D008214:Lymphocytes / Q000166:cytology; D008223:Lymphoma / Q000097:blood / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous